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The peptide drug candidate NAP (davunetide) has demonstrated protective eﬀects in various in vivo and in vitro models
of neurodegeneration. NAP was shown to reduce tau hyperphosphorylation as well as to prevent caspase-3 activation and
cytochrome-3 release from mitochondria, both characteristic of apoptotic cell death. Recent studies suggest that caspases may
play a role in tau pathology. The purpose of this study was to evaluate the eﬀect of NAP on tau hyperphosphorylation and
caspaseactivityinthesamebiologicalsystem.Ourexperimentalsetupusedprimaryneuronalculturessubjectedtooxygen-glucose
deprivation (OGD), with and without NAP or caspase inhibitor. Cell viability was assessed by measuring mitochondrial activity
(MTS assay), and immunoblots were used for analyzing protein level. It was shown that apoptosis was responsible for all cell
death occurring following ischemia, and NAP treatment showed a concentration-dependent protection from cell death. Ischemia
caused an increase in the levels of active caspase-3 and hyperphosphorylated tau, both of which were prevented by either NAP
or caspase-inhibitor treatment. Our data suggest that, in this model system, caspase activation may be an upstream event to tau
hyperphosphorylation, although additional studies will be required to fully elucidate the cascade of events.
1.Introduction
NAP is an 8 amino acid peptide, which was identiﬁed as
an active neuroprotective fragment of activity-dependent
neuroprotective protein (ADNP) [1]. NAP was found to be
neuroprotective in various in vivo and in vitro models of
neurodegeneration [2]. NAP treatment was shown to reduce
twomajorpathologicalmarkers—tauhyperphosphorylation
[3–5] and caspase-3 activation/apoptosis [6, 7]. Hyper-
phosphorylated and aggregated tau, originally detected in
Alzheimer’s disease (AD) brains by Grundke-Iqbal and
colleagues [8], is a hallmark of a group of diseases, generally
referred to as “tauopathies” which diﬀer from each other
by genetic background and by additional pathological and
phenotypic characteristics [9].
Tau is a microtubule-associated protein (MAP) which
promotes microtubule stabilization. The ﬁrst study that
reported disassembly of microtubules from AD brain due
to the abnormal hyperphosphorylation of tau was by Iqbal
et al. [10]. Hyperphosphorylated tau loses its microtubule
aﬃnity causing a change in microtubule dynamics towards
disassembly [11–16] and further accumulation of aggregated
tau. Alonso et al. originally showed that AD abnormal
hyperphosphorylation of tau causes not only loss of function
but also the gain of toxic function, with hyperphosphory-
lated tau blocking microtubule assembly in the presence of
normal tau [17] and promoting the formation of normal
tau containing tangles [18]. The most prevalent tauopathy
is Alzheimer’s disease (AD), and other tauopathies include
a selection of frontotemporal dementia/degeneration, with
pure tauopathies like progressive supranuclear palsy (PSP)
[19].
One of the hallmarks of tauopathies is the accumula-
tion of neuroﬁbrillary tangles (NFTs). NFT accumulation
correlates with the severity of dementia and memory loss
[20–22] and with neuronal degeneration in AD and PSP
[23, 24]. Recent studies associated the spread of tauopathies
with propagation of prion-like protein inclusions [25]a n d
suggested transsynaptic spread of tau [26]. However, several
studies showed that soluble defective tau is also correlated2 International Journal of Alzheimer’s Disease
Table 1: Models of NAP protection against tau pathology or increased markers of apoptosis.
Models of tau pathology detecting protective eﬀects when treated with NAP
(i) Transgenic ADNP heterozygous mouse [4]
(ii) Transgenic human double-mutant tau mouse [5]
(iii)Tripletransgenicmiceexpressingtheamyloid(Aβ)precursorproteinAPP(Swe),presenilinPS1(M146V),andtau(P301L)[45,46]
(iv) Mixed neuroglial primary cultures treated with Aβ (1–42, 2.5μM) [3]
(v) Primary cultures of astrocytes [47]
Models of apoptosis detecting protective eﬀects when treated with NAP
(i) A stroke model using spontaneously hypertensive rats which underwent permanent middle cerebral artery occlusion [48]
(ii) A rat model of diabetes (streptozocin toxicity) [7]
(iii) A rat model of epilepsy [49]
(iv) PC-12 cells exposed to H2O2 [50]
(v) Primary neuronal cultures subjected to ischemia/ reperfusion schedule of 3h/3h [39]
with cognitive deﬁcits [27–29], causing synaptic loss and
gliosis before NFTs formation [30]. Tau is also a substrate of
multiple caspases, which cleave it and promote its pathologic
aggregation [31–33]. Cleaved and hyperphosphorylated tau
is found in deposits in AD brains, and it was found that
truncated tau promotes apoptosis [34]. The relationship
between tau hyperphosphorylation and cleavage is not
completely understood. Though some evidence suggests that
caspase cleavage of tau is not necessary for tau hyperphos-
phorylation, this question should be further clariﬁed [35,
36]. Caspases are known to play a role in AD (for review,
see [37]), and caspase eﬀects on modiﬁcations of tau are of
a great interest. Furthermore, treatment of an AD mouse
model with a broad-spectrum caspase inhibitor was lately
shown to reduce tau pathology but not amyloid-β (Aβ)
pathology [38].
To date, we have tested NAP eﬀects on either tau hyper-
phosphorylation or oncaspaseactivationin separatemodels,
showing inhibition of tau pathology or inhibition of caspase
activation (or other apoptotic markers) (Table 1). The data
emerging from these studies raise the question whether there
is a dependency between the eﬀects of NAP on the two
pathologies. In the current study, we used an in vitro model
of ischemia in which NAP treatment reduced apoptosis [39].
As animal models of ischemia exhibit tau hyperphosphory-
lation [40–42], we investigated whether the in vitro ischemia
model mimics the in vivo situation. Thus, the aim of the
current study was to identify a possible interaction between
caspase activity and tau hyperphosphorylation, and to test
the eﬀect of NAP on both events under ischemic conditions.
2.MaterialsandMethods
All procedures involving animals were approved by the
Animal Care Committee of Tel-Aviv University and further
approved by the Israel Health Authorities.
2.1. Primary Neuronal Cultures. Primary neuronal cultures
were produced from cortices obtained from 1-2-day-old
Sprague-Dawley rat pups. Pups were decapitated, their skulls
were removed, and their cortices were transferred to a Petri
dish ﬁeld with HBSS-HEPES buﬀer. Meninges were removed
using tweezers under binocular. Neurons were produced
with Worthington’s papain dissociation kit (Worthington,
cat.LK003150) according to the manufacturer’s instructions.
The cells were seeded in Neurobasal-A media (Invitrogen,
cat. 10888022) fortiﬁed with 1% Glutamax supplement
(Invitrogen, cat. 35050038) and 1% Neurocalm (Stemcells
technologies, cat. 05711). All tests were executed 5-6 days in
vitro (DIV).
2.2. Antibodies. The following antibodies were used for
immuneﬂuorescence: NeuN (Neuronal Nuclei, Chemicon,
cat. MAB377), diluted 1:100, and GFAP (glial ﬁbrillary
acidic protein, Abcam, cat. 7260), diluted 1:500. The
following antibodies were used for immunoblot analysis:
p-tau202 (Anaspec, cat. 28017) 0.25μg/mL, total tau (MBL
international, cat. AT-5004) 0.5μg/mL, and active caspase-
3 (Abcam, cat. 2302) 1μg/mL. Fluorophore and horseradish
peroxidase conjugated secondary antibodies were purchased
from Jackson ImmunoResearch Laboratories Inc.
2.3. Analysis of Culture Purity. Cells were seeded in 24 well
plates on poly-D lysine- (PDL-) coated coverslips (Sigma-
Aldrich, cat. p-6407) at a density of 0.5∗105cells/well. At 5–
6 DIV, the cultures were ﬁxed using a 4% paraformaldehyde
(PFA) solution. Antigen retrieval, if needed, was performed
by boiling the sample in sodium citrate buﬀer (pH = 6) for
20 minutes. Permeabilization was performed with a 0.2%
Triton-X solution. Nonspeciﬁc antigen binding was blocked
byincubationina2%bovineserumalbumin(BSA)solution,
then primary antibody (Ab) diluted in primary antibody
diluent (Biotech applications, cat. MSBA-AbDil) was added
for 1 hour at RT. Cells were washed three times in 2% solu-
tion of BSA and incubated in secondary antibody solution
for 30 minutes in the dark. After an additional wash, PBS +
DAPI (4 ,6-diamidino-2-phenylindole, a ﬂuorescent stain
that binds strongly to A–T-rich regions in DNA, Invitrogen)
was applied for 5 minutes, in order to stain cell nuclei. The
coverslipswereputonanantifadingbuﬀeronacarrierslides.
For analysis of culture purity, we used 3 cultures produced
independently. We used Zeiss ﬂuorescence microscope andInternational Journal of Alzheimer’s Disease 3
camera to obtain 10 pictures (×20 magniﬁcation) from each
culture. Each picture contained a minimum of 30 cells.
NeuN-positive and GFAP-negative cells were considered
neuronal and were expressed as % of the total DAPI count.
2.4. OGD Treatment. Cells were seeded on PDL-coated
plates employing two diﬀerent plating conditions (Corning):
(1) 10cm Petri dishes, 6 ∗ 106 cells per dish (for protein
extraction), and (2) 48 well plates 0.5 ∗ 105 cells/well (for
viability tests). After 5-6 DIV, the condition media (CM)
was collected, ﬁltered, and kept at 37◦C. Cultures were
washed twice with 37◦C PBS, and the experimental media
was added (PBS for the OGD groups, fresh media for the
control group). Treatments were added to the experimental
media(QVD-OPH,abroad-spectrumcaspaseinhibitor[43],
20μM diluted in DMSO (Biovision, cat. no. 1170) or 10
−5 M
NAP diluted in PBS or diluents only). The culture dishes
were placed in an ischemic chamber (Billups-Rothenberg,
Inc., cat. MIC 101) which was ﬁlled with a 5%CO2/95%N2
gas mixture and sealed, and the chamber was placed in an
incubator for 2 hours; at 37◦C. Two experimental modes
were applied, in the ﬁrst one (used for NAP protecting
concentration curve), gassing was for 25 minutes followed
by sealing for 2 hours, in the second paradigm (used
for calibration of caspase inhibition and protein analysis),
gassingwasfor5minutesonly.O2 percentagewasmonitored
with O2 meter (HUMIL International Corporation, cat.
PO2-250)anddidnotexceed1.2%anytimeduringtheOGD
period. At the end of the OGD period, the culture dishes
were removed from the chamber. For protein extraction, the
experimental media was removed and protein was extracted
as described below.
2.5. Viability Assay. Cells were seeded in 48 well plates at a
density of 0.5∗105 cells/well (as described above). Following
the OGD period, the condition media (CM) which was
removed at the initiation of the OGD treatment (see above)
was reapplied to the corresponding treatments. The MTS
assay was used to assess viability (Promega, cat. G3580).
Absorbance at 490nm was measured in a SpectraMAX
190 plate reader, (Molecular Devices, Inc.). The results
were analyzed using SoftMax Pro software version/year
(Molecular Devices, Inc.) and expressed as % of the control.
The results summarize 3 independent experiments with 5
replicates per treatment per experiment. Data are presented
as means/medians ± SE.
2.6. Immunoblots. Immediately after OGD treatment (fol-
lowing gassing mode of 5 minutes of gassing and 2 hours
OGD period), experimental media was discarded, and the
dishes were washed twice with PBS. Protein was extracted
using RIPA buﬀer with anti-proteases (ROCHE, cat. 11
873 580 001) and anti-phosphatases. Protein concentration
was quantiﬁed using Pierce BCA protein assay reagents
(Pierce, cat. 23223, 23224) with bovine serum albumin
(BSA) as a standard protein. Equal amounts of protein
diluted in sample buﬀer were separated by sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis (12% gels
or 4–20% gradient gels, nUView, cat. NG21-420). Proteins
were transferred to nitrocellulose membranes using standard
techniques, as before [44]. Membranes were blocked with
5% BSA in Tris-buﬀered saline containing 0.1% Tween-20
(TBSt) and then incubated overnight with primary antibody.
Membranes were washed 3 times with TBSt and incubated
with secondary Ab for 1 hour at RT. Pierce ELC substrate or
Pierce super signal ECL was used to visualize proteins (cat.
32106, 34080). Signal density was detected with the DNR
bioimaging systemsMiniBIS pro (DNR Bio-Imaging Systems
Ltd.) and TotalLab TL-100 software (Nonlinear Dynamics
Ltd.).
2.7. Statistical Analysis. SPSS 19.0 for windows (http://
www-01.ibm.com/software/analytics/spss/) was used for sta-
tistical analysis. For viability assessment, 3 independent
experiments were conducted with 5 trials per treatment
in each experiment. Data were analyzed using a one-way
ANOVA with 5% selected the level of signiﬁcance, and post
hoc Scheﬀe and LSD corrections. The eﬀect of NAP was
evaluated in 14 independent experiments, of which in 4
experiments QVD-OPH eﬀect was also tested, and the levels
of signiﬁcance were evaluated using ANOVA with post hoc
LSD.
3. Results
3.1. Characterization of Culture Purity. Culture purity was
analyzedusingimmunoﬂuorescentstainingwithcell-speciﬁc
markers. After 5-6 DIV (days in vitro), 95.9 ± 0.96% (SEM)
of the cells (counted using nuclear DAPI stain) were positive
fortheneuronalNeuNmarkerandnegativefortheastrocytic
marker, GFAP. A representative immuneﬂuorescence stain in
Figure 1 shows neuronal cells stained with NeuN in red, and
astrocytes stained with GFAP in green.
3.2. NAP Protective Eﬀect Following 2 Hours of OGD. Cell
viability was evaluated following a 25-minute gassing period
and an additional 2 hours of OGD. The results were calcu-
lated and expressed as % of the control group (Figure 2).
Under this paradigm, ∼70% cell death was observed.
Treatment with NAP increased cell viability immediately
following OGD (F = 17.667, df = 7, P<0.001).
Post hoc pairwise comparisons (LSD) indicated that NAP
concentrations of 10
−7 Ma n d1 0
−5 M signiﬁcantly protected
against ischemia (Figure 2, P ≤ 0.05).
3.3. Apoptosis Was the Main Type of Cell-Death Following 2
Hours of OGD. Using the broad spectrum caspase inhibitor
QVD-OPH,wetestedtheextentofapoptoticdeathfollowing
5-minute of gassing and 2 hours of OGD. Cell viability was
evaluated and compared to the control group (Figure 3).
Under this paradigm, ∼55% cell death was observed. Here,
QVD-OPH (2 ∗ 10
−5 M) treatment signiﬁcantly increased
cell viability to the control levels. In the same experiment,
NAP in the same experiment, NAP (10
−5 M) treatment
rescued from the apoptotic cell death (F = 16.090, df = 7,
P<0.001).Posthocpairwisecomparisonsdidnotdetectany4 International Journal of Alzheimer’s Disease
Figure 1: Culture purity: at 5-6 DIV, cells were ﬁxed and
immunoﬂuorescence staining was performed using the astrocyte
marker GFAP (green), the neuronal marker NeuN (red), and
DAPI stain (blue) for nuclei. Quantiﬁcation of neuronal cells was
done using 10 random ﬁelds from each of 3 experiments (×20
magniﬁcation). 95.9 ± 0.96% of the total cells (DAPI stain) were
recognized as neurons (NeuN positive, GFAP negative).
signiﬁcant diﬀerences between the caspase inhibitor, NAP,
and control no-ischemia groups.
3.4. Active Caspase-3 Expression Was Increased Following
OGD and Reduced Due to NAP Treatment. The levels of
active caspase-3 were evaluated immediately after the OGD
period using immunoblots with a speciﬁc active caspase-3
antibody and further quantiﬁed and normalized to actin.
As shown in a representative blot in Figure 4(a),O G D
treatment increased active caspases-3 levels. This increase
was prevented by NAP treatment (10
−5 M) or QVD-OPH
(caspase inhibitor) treatment (2 ∗ 10
−5 M). Figure 4(b)
depictsthelevelofactivecaspase-3expressedas%ofcontrol.
A signiﬁcant increase in active caspase-3 expression was
induced by OGD and partially but signiﬁcantly prevented by
NAP treatment (F = 7.880, df = 2, P = 0.004).
3.5. Tau Hyperphosphorylation Was Increased Following 2
Hours of OGD; P-Tau Increase Was Prevented by Either NAP
Treatment or QVD-OPH Treatment. phospho-tau (p-tau)
levels were detected by immunoblot, with a p-tau202-speciﬁc
antibody. A representative blot is shown in Figure 5(a).P -
tau levels, were quantiﬁed, normalized to total tau levels
and expressed as % of the p-tau levels in the control
culture (Figure 5(b)). Phospho-tau levels were signiﬁcantly
increased following the OGD insult. Both NAP treatment
(10
−5 M) and QVD-OPH (caspases inhibitor) treatment
(2 ∗ 10
−5 M) prevented p-tau increase (ANOVA with post
hoc LSD, P ≤ 0.05), (F = 5.633, df = 2,P = 0.012).
4. Discussion
Focusing on the protective properties of NAP, two central
characteristics of neurodegeneration have been shown to
be inhibited by NAP treatment both in vivo and in vitro:
tau hyperphosphorylation [3–5]a n da p o p t o s i s[ 6, 7, 51].
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Figure 2 :N A Pp r o t e c t sf r o mc e l ld e a t hi nad o s ed e p e n d e n t
manner following 2 hours of OGD insult, but not after additional
24 hours reperfusion. Primary neuronal cultures (5-6DIV) were
subjected to 2h of ischemic insult. Cell viability was evaluated
using MTS viability assay. Data was normalized to % of control.
Results are shown as mean ± SE. ∗Signiﬁcantly diﬀerent from
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be P ≤ 0.05). Using LSD post hoc, NAP 10
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Figure 3: Following 2 hours of OGD, cells died exclusively from
apoptosis.CulturesweretreatedwitheitherNAP(10
−5 M)orQVD-
OPH (2 ∗ 10
−5 M) and subjected to 2h of ischemic insult. Cell
viability was evaluated immediately following the ischemic period
using MTS viability assay. Data was normalized to % of control.
Results are shown as mean ± SE; ∗signiﬁcantly diﬀerent from all
other groups, P ≤ 0.05 (ANOVA, with post hoc Scheﬀe).
association between these two pathological cascades. Our
experimental setup used primary neuronal cultures (95.9 ±
0.96% purity), subjected to 2 hours of OGD with no
reperfusion period. Under this paradigm, apoptosis was
found to be responsible for all cell death in that it was
inhibited by QVD-OPH. Our results showed that inhibition
of caspase activity prevented tau hyperphosphorylation,
leading us to conclude that in the current experimentalInternational Journal of Alzheimer’s Disease 5
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Figure 4: An increase in active caspase-3 levels induced by 2 hours of OGD was diminished by NAP treatment (10
−5 M). Cultures were
treated with 10
−5 MN A Po rw i t h2 0μM QVD-OPH (broad spectrum caspase inhibitor) exposed to OGD insult for 2 hours. Proteins were
extracted and analyzed using immunoblot with a speciﬁc antiactive caspase-3 antibody. A representative blot of active caspase-3 antibody is
exhibited in (a). (ANOVA with post hoc LSD, P ≤ 0.05) (b).
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Figure 5: 2 hours of OGD caused an increase in p-tau202 levels, prevented by either NAP or QVD-OPH treatment. Cultures were treated
with 10
−5 MN A Po rw i t h2 0μM QVD-OPH (broad spectrum caspase inhibitor, indicated as OGD + Q) and exposed to OGD insult for 2
hours. Proteins were extracted and analyzed using immunoblot with a speciﬁc anti-p-tau202 and antitotal tau antibodies. A representative
blot of p-tau202 and total tau is exhibited in (a). P-tau levels were quantiﬁed and normalized to total tau levels (ANOVA with post hoc LSD,
P ≤ 0.05) (b).
and cellular conditions, caspase activation is an upstream
event to tau hyperphosphorylation. We further evaluated
the eﬀect of NAP on cell viability, caspase-3 activation, and
tau hyperphosphorylation. Viability assays showed that NAP
treatment rescued cells from apoptosis as demonstrated by
the reduction in active caspases-3 following NAP treatment.
NAP treatment also prevented tau hyperphosphorylation
after the OGD. Combining the eﬀect of NAP on active
caspases-3 and tau hyperphosphorylation, it seems likely
that caspases-3 or an upstream pathway is targeted by NAP
activity in isolated neuronal cells that are metabolically
stressed.
A careful look should be given to the concentrations
by which NAP had a signiﬁcant protective eﬀect. Previous
data,includingischemia-reperfusionexperimentsconducted
in primary neuronal and neuroglial cultures, exhibited pro-
tection from cytochrome-c release, microtubule breakdown
and reduction in MAP2 intensity using NAP concentrations
of 10
−15 M–10
−8 M[ 39, 52]. Though most studies used
femtomolar concentration of NAP, Pascual and Guerri [53]
used concentration of 10−7M to show NAP protection in
a model neurons cocultured with astrocytes obtained from
prenatal ethanol-exposed fetuses. In our model, protection
was detected when treating with NAP at concentrations
≥10−7 M. The diﬀerences in the potent NAP concentration
could be explained by the combination of the acute insult
applied to a relatively pure culture of immature neurons.
Immature neurons (2–4 DIV) in a pure neuronal culture
(99% purity) were shown to go through spontaneous apop-
totic death which was prevented when astrocyte condition
media was added to the neuronal cultures. In comparison
to neuroglial mixed culture, pure neuronal cultures were
also found to be more sensitive to excitotoxic insult that
also plays a role in the ischemia induced cell death [54].
We have previously shown that neuronal protection in the
absence of glia required increased concentrations of NAP as6 International Journal of Alzheimer’s Disease
compared to mixed neuroglial cultures [55]. Furthermore,
the original discovery of the NAP containing protein, ADNP,
was as a glial protein providing neuroprotection. ADNP is
essential for central nervous system development, expressed
in speciﬁc brain tissue in the adult brain [1], and is also
deregulated and may be overexpressed following acute brain
damage [56] and in animal models of neurodegeneration
[57, 58]. ADNP-like immunoreactivity is secreted from glial
cells [59] further providing neuronal protection [4, 53, 60].
In this respect, NAP protected against ADNP deﬁciencies as
outlined in the Introduction [4]. NAP was further shown
to promote neurite outgrowth [61, 62] provide microtubule
stabilization[63]andprotectneuronsinabroadspectrumof
neuropathologies models [2]. Importantly, NAP also showed
glial protection in vitro [64] and in vivo [7].
Insummary,wedemonstratedthatNAPreducescaspase-
3 activation, and tau hyperphosphorylation, suggesting that
caspase-3 or upstream pathways may be targets for NAP
activity. We believe these data provide additional insights
regarding the molecular mechanism for NAP’s neuropro-
tective activity and the intricate interaction between micro-
tubules/tau and apoptotic mechanisms.
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